echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Endocrine System > JAHA: PCSK9 inhibitor use in patients with atherosclerotic disease

    JAHA: PCSK9 inhibitor use in patients with atherosclerotic disease

    • Last Update: 2021-05-08
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Proprotein convertase subtilisin 9 (PCSK9) inhibitor is a promising lipid-lowering drug, although its use is limited by cost.

    Recently, the medsci.
    cn/course/search.
    do?w=%E5%BF%83%E8%A1%80%E7%AE%A1">heart blood vessels published on the prestigious journal JAHA the areas of disease research article, this retrospective cohort study using a national commercial claims database, which included age, atherosclerotic cardiovascular between 18-64 years old Disease (ASCVD) patients.

    medsci.
    cn/course/search.
    do?w=%E5%BF%83%E8%A1%80%E7%AE%A1">Heart blood vessels

    The researchers determined from the third quarter of 2015 to the second quarter of 2019, the US Food and Drug Administration the number of Board approved start using the PCSK9 inhibitors ASCVD patients.
    The secondary goal of the study is to clarify the proportion of patients who use PCSK9 inhibitors in various ASCVD risk groups.
    They
    are risk stratified based on statin use and baseline low-density lipoprotein
    cholesterol levels.

    Manage cholesterol

    Researchers identified 126,419 ASCVD patients who were treated with PCSK9 inhibitors or statins.
    Among these patients, 1168 (0.
    9%) received PCSK9 inhibitor therapy.
    The number of patients receiving PCSK9 inhibitor treatment increased from 2 patients in the third quarter of 2015 to 119 patients in the second quarter of 2019, which is equivalent to the proportion of patients who have received statin therapy starting PCSK9 inhibitor therapy from 0.
    05 % Increased to 2.
    5%.
    Among ASCVD patients who were highly compliant with high-intensity statins, 13643 patients had low-density lipoprotein cholesterol ≥70 mg/dL.
    In this subgroup, 119 patients (0.
    9%) started PCSK9 inhibitor therapy.

    It can be seen that although there is more and more evidence of efficacy trials, the guidelines recommend the use of PCSK9 inhibitors in high-risk ASCVD patients, but from 2015 to 2019, very few patients started to use PCSK9 inhibitors.
    The price drop may not be enough to affect the use of PCSK9 inhibitors
    .

    Although there is increasing evidence of efficacy trials and guidelines recommend the use of PCSK9 inhibitors in high-risk ASCVD patients, from 2015 to 2019, few patients started using PCSK9 inhibitors.
    The price drop may not be enough to affect the use of PCSK9 inhibitors

    Original source:

    Original source:

    Elias J.
    Dayoub.
    et al.
    Adoption of PCSK9 Inhibitors Among Patients With Atherosclerotic Disease .
    J AM HEART ASSOC.
    2021.
    href="" target="_blank" rel="noopener">Adoption of PCSK9 Inhibitors Among Patients With Atherosclerotic Disease

    Leave a message here

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.
    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.